1-2 of 2
Steven I. Sherman
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

ONC201 Shows Potent Anticancer Activity Against Medullary Thyroid Cancer via Transcriptional Inhibition of RET, VEGFR2, and IGFBP2

Rozita Bagheri-Yarmand, Ramona Dadu, Lei Ye, Yaashmin Shiny Jebaraj, Jade A. Martinez, Junsheng Ma, Rohinton S. Tarapore, Joshua E. Allen, Steven I. Sherman, Michelle D. Williams, Robert F. Gagel
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (4): 665–675.
https://doi.org/10.1158/1535-7163.MCT-20-0386
Published: 01 April 2021
View article titled, ONC201 Shows Potent Anticancer Activity Against Medullary Thyroid Cancer via Transcriptional Inhibition of <em>RET</em>, <em>VEGFR2</em>, and <em>IGFBP2</em>
Open the PDF for ONC201 Shows Potent Anticancer Activity Against Medullary Thyroid Cancer via Transcriptional Inhibition of <em>RET</em>, <em>VEGFR2</em>, and <em>IGFBP2</em> in another window
Journal Articles

Abstract LB-C17: A phase I study of everolimus (mTOR inhibitor) in combination with vandetanib (multikinase inhibitor of VEGFR, EGFR, and RET) in advanced solid tumors including molecularly matched aberrations

Tina Cascone, Kenneth R. Hess, Sarina Piha-Paul, David S. Hong, Michael Roxas, Ishwaria M. Subbiah, Siquing Fu, Aung Naing, Filip Janku, Daniel Karp, Steven I. Sherman, Funda Meric-Bernstam, John V. Heymach, Vivek Subbiah
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): LB-C17.
https://doi.org/10.1158/1535-7163.TARG-15-LB-C17
Published: 01 December 2015
View article titled, Abstract LB-C17: A phase I study of everolimus (mTOR inhibitor) in combination with vandetanib (multikinase inhibitor of VEGFR, EGFR, and RET) in advanced solid tumors including molecularly matched aberrations